A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

ConSynance Therapeutics

Status and phase

Completed

Phase 1

Conditions

Prader-Willi Syndrome

Treatments

Drug: CSTI-500

Study type

Interventional

Funder types

Industry

Identifiers

NCT05504395

CSTI-500-003

Details and patient eligibility

About

The purpose of this Phase 1 study is to evaluate the pharmacokinetics (PK) and safety of a single dose of CSTI-500 10 mg in subjects with Prader-Willi syndrome (PWS) between 13 and 50 years of age with a genetically confirmed diagnosis of PWS.

Full description

This is an open-label, single center, Phase 1 study to evaluate the PK and safety of a 10 mg single oral dose of CSTI-500, a triple monoamine reuptake inhibitor (TRI), in patients with genetically confirmed PWS. The study will consist of a Screening Period of up to 1-3 days prior to the Baseline Visit (Visit 2). In addition to the Screening Visit (Visit 1), eligible subjects will attend five in-clinic site visits for PK blood draws and safety assessments over a 6-day period. At Visit 2 all subjects will receive one single oral dose of CSTI-500 10 mg. Approximately 14 patients aged 13 to 50 years who meet all eligibility criteria will receive one single dose of CSTI-500.

Enrollment

10 patients

Sex

All

Ages

13 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female subjects (13-50 years of age at screening) with a documented medical record history of PWS confirmed by genetic testing.
Subject must have a reliable caregiver/parent to bring the subject to the site for the visits, remain with the subject during visit times when allowed to be with the subject and respond to any questions during the visits.
Female subjects must not be pregnant or lactating and be willing to use double barrier birth control method throughout the study.
A normal supine systolic blood pressure must be ≤140 mmHg and ≥100 mmHg; diastolic blood pressure must be ≤80 mmHg and ≥60 mmHg at Screening. Pulse rate must be ≥50 bpm and ≤100 bpm and pulse rate increase on standing must be within acceptable range.
All concomitant medications including blood pressure medications and type 2 diabetic medications must be stable for ≥3 months prior to screening (≤10% change). Supplements and vitamins are not considered concomitant medications for eligibility purposes.

Exclusion criteria

Participation in any clinical study with an investigational drug/device within 3 months prior to screening or during the study.
Recent use (within 3 months) of weight loss agents including prescription, herbal medications, and weight loss supplements.
Major surgery within 6 months of screening or planned during the study or history of bariatric surgery.
Any malignancy in the 2 years prior to screening (excluding basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
Current liver, pulmonary, cardiac, or GI disease that would be expected to adversely affect study participation. Stable disease, e.g., asthma or controlled hypertension is not excluded. Liver disease or liver injury as indicated by abnormal liver function tests, ALT, AST, alkaline phosphatase, or serum bilirubin (≥3X ULN for any of these tests).
Unexplained history or presence of combination of unexplained symptoms e.g., dizziness, syncope, fatigue, palpitations/tachycardia, headaches, or exercise intolerance.
Heart failure classified per the New York Heart Association (NYHA) level II or greater.
Myocardial infarction, stroke, or confirmed TIA within the last 5 years.
Uncontrolled Type 2 diabetes as defined by HbA1c ≥ 9% at Screening.
Insulin-dependent Type 1 diabetes.
Subjects with a history of any suicidal behavior.
Inability to swallow the oral capsule whole with water.